𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer

✍ Scribed by Hidde J. Haisma; Anne Battaile; Earl W. Stradtman; Robert C. Knapp; Vincent R. Zurawski Jr.

Publisher
John Wiley and Sons
Year
1987
Tongue
French
Weight
553 KB
Volume
40
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Monoclonal antibody (MAb) O C 125 binds to approximately 80% of epithelial ovarian cancers. Serum antigen, CAI25, can be detected in these patients. "'I-OC 125-F(ab')2 was injected into 5 ovarian carcinoma patients with preinjection serum levels of I50 to 9,000 CAI25 U/ml. Patients received the antibody intravenously in doses ranging from 0.46 to 0.94 mg with a specific activity of approximately 2.5 mCilmg '"I. The halflife in the circulation was approximately 30 hr and was independent of serum CAI25 levels. Clearance of "'I from the circulation fitted an open, one-compartment mathematical model. Gel filtration chromatography revealed antibody-antigen complexes in sera 15 min after injection of the radiolabelled antibody. By 5 days after injection, the free form of OC125 antibody could not be detected in the serum. The rate of complex formation correlated well with the observed preinjection serum CA 125 levels. This direct correlation was verified in vitro using purified CAI25 antigen and radiolabelled OC125 F(ab')2 fragments. The specific effects of complex formation on tumor localization remains unclear. However, the presence of complexes should not be ignored, when planning for diagnostic imaging or immunotherapy with OCl25 or other MAbs reacting with circulating antigen.

πŸ“œ SIMILAR VOLUMES

Distribution of radiolabelled anti-CA125
Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(abβ€²)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients
✍ Martina M. Uttenreuther-Fischer; Herbert Feistel; Friedrich Wolf; Wolfram JΓ€ger πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 76 KB

Ovarian cancer is a highly malignant tumor of mainly postmenopausal women. The long-term prognosis of this malignancy is largely determined by micrometastasis present at the time of second-look surgery. In general, patients face a poor outcome. New radio-immunoscintigraphic methods to target tumor t

Level of anti-mouse-antibody response in
Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival
✍ Silvia Miotti; Donatella R.M. Negri; Olga Valota; Marcella Calabrese; Reinder L. πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 88 KB

More than 60% of cancer patients injected with intact murine monoclonal antibody (MAb) develop a humoral response against the antigen even after a single dose. Analysis of a series of 35 ovarian-cancer patients entered in phase-I and -II clinical studies of T-cells retargeted with the bi-specific F(

Monoclonal antibody 4D3 detects small in
Monoclonal antibody 4D3 detects small intestinal mucin antigen (SIMA)β€”Glycoprotein in the serum of patients with colorectal cancer
✍ Gideon D. Pinczower; Robert D. Gianello; Roderick P. W. Williams; Barry N. Prest πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 French βš– 663 KB

We have developed a sensitive ELISA using MAb 4D3 for the detection of a novel epitope on Small Intestinal Mucin Antigen (SIMA) and report here that SlMA is present in the serum of patients with colorectal cancer. SlMA has been shown to occur in tissue from a high proportion of patients with colorec